Outset Medical appoints Renee Gaeta as CFO, succeeding Nabeel Ahmed, to drive growth and profitability.
Quiver AI Summary
Outset Medical, Inc. has appointed Renee Gaeta as its new Chief Financial Officer, effective immediately, succeeding Nabeel Ahmed who is leaving for other opportunities. Gaeta brings extensive financial and leadership experience from her previous roles at publicly traded medical device companies, including her most recent position as CFO of Shockwave Medical. Outset's Chair and CEO, Leslie Trigg, expressed confidence in Gaeta's ability to lead the company as it aims for growth and profitability. Outset also reaffirmed its financial guidance for 2025, projecting revenues between $115 million and $125 million with a non-GAAP gross margin in the high-30% range. The company's innovative Tablo Hemodialysis System aims to simplify and enhance the dialysis experience across various care settings.
Potential Positives
- Appointment of Renee Gaeta as CFO brings extensive financial and leadership experience, which is critical for Outset’s strategy to drive growth and achieve profitability.
- Outset reiterated its 2025 financial guidance, forecasting revenues between $115 million to $125 million, demonstrating confidence in its business outlook.
- The Tablo® Hemodialysis System represents an innovative approach to dialysis, which could enhance patient care and operational efficiency for providers, supporting the company’s market position.
Potential Negatives
- The departure of the former CFO, Nabeel Ahmed, without further details on his reasons may raise concerns about potential instability or issues within the company.
- The reiteration of financial guidance amidst the leadership change could indicate uncertainty about future performance and profitability, which may alarm investors.
- Actual future results may differ significantly from the forward-looking statements provided, creating potential volatility and uncertainty for stakeholders.
FAQ
Who is the new CFO of Outset Medical?
Renee Gaeta has been appointed as the Chief Financial Officer of Outset Medical, effective immediately.
What prior experience does Renee Gaeta have?
Renee Gaeta has served as CFO at Shockwave Medical and Eko Health, with extensive leadership in medical-device companies.
What are Outset Medical's financial expectations for 2025?
Outset reaffirms its 2025 financial guidance, expecting revenues between $115 million and $125 million.
What technology does Outset Medical pioneer?
Outset Medical pioneers the Tablo Hemodialysis System, a technology that simplifies dialysis care and reduces costs.
What is the significance of the Tablo system?
Tablo enables dialysis to be delivered anywhere with integrated water purification and data analytics, enhancing patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 6 sales selling 109,625 shares for an estimated $108,938.
- NABEEL AHMED (Chief Financial Officer) has made 0 purchases and 7 sales selling 74,397 shares for an estimated $71,506.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 7 sales selling 61,535 shares for an estimated $57,557.
- MARC NASH (SVP Operations and R&D) has made 0 purchases and 8 sales selling 43,408 shares for an estimated $39,938.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OM Hedge Fund Activity
We have seen 8 institutional investors add shares of $OM stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DURABLE CAPITAL PARTNERS LP added 1,740,216 shares (+inf%) to their portfolio in Q1 2025, for an estimated $19,246,788
- ALYESKA INVESTMENT GROUP, L.P. added 1,703,083 shares (+inf%) to their portfolio in Q1 2025, for an estimated $18,836,097
- PFM HEALTH SCIENCES, LP added 1,685,727 shares (+inf%) to their portfolio in Q1 2025, for an estimated $18,644,140
- WOODLINE PARTNERS LP added 1,325,784 shares (+inf%) to their portfolio in Q1 2025, for an estimated $14,663,171
- AMERIPRISE FINANCIAL INC removed 120,682 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,009,355
- GMT CAPITAL CORP removed 98,114 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,085,140
- MUBADALA INVESTMENT CO PJSC removed 96,040 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,599,065
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset’s Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities.
“Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companies as both a CFO and board member,” said Leslie Trigg, Chair and CEO. “She is the ideal fit for Outset as we drive our next phase of growth and our goal to achieve near-term profitability. I want to thank Nabeel for his contributions to Outset and wish him well in his future endeavors.”
With today’s announcement, Outset also reiterated its 2025 financial guidance, including expected revenue of $115 million to $125 million and non-GAAP gross margin in the high-30% range.
Ms. Gaeta most recently served as CFO of Shockwave Medical until its $13 billion acquisition by Johnson and Johnson in May 2024. She was previously CFO at Eko Health, where she also led both finance and human resources, and Establishment Labs, where she played a key role in the company’s initial public offering and growing the global business. She has served as a member of the board of directors and the audit committee of Candel Therapeutics since August 2022 and was previously audit committee chair and a board director of SeaSpine Holdings from 2019 until its acquisition in 2023 by Orthofix Medical. She received her Bachelor of Science, cum laude, in accounting from Loyola Marymount University and is a Certified Public Accountant in California.
“Outset is transforming dialysis care, and I am honored to join the company as its next CFO,” said Ms. Gaeta. “Tablo offers clear and compelling clinical, financial and operational value to acute, post-acute and home dialysis providers. I look forward to playing an important role in helping drive Outset to achieve its growth and profitability goals.”
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues and non-GAAP gross margin. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the company’s filings with the Securities and Exchange Commission, including its most recent annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact
Jim Mazzola
Investor Relations
[email protected]